You are here

Home » Content

KSENOTRANSPLANTASYONUN İMMÜNOLOJİK YÖNÜ

IMMUNOLOGIC SIDES OF XENOTRANSPLANTATION

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1995

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Xenotransplantation is viewed as the most promising way to overcome the problems of shortage of donor organ. It can be exploited from rapidly expanding capabilities in genetic engineeringfor xenotransplan-tation. The major immunological hurdle to tissue or organ transplantations between phylogenetically-dis-tant individuals is humoral immunity. In particular, immonupathologic effecs mediated by the reaction of natural antibodies and complement of recipient with graft endothelium in the donor organ cause xenograft rejection. Nevertheless, the phenomenon called "accomodation" that will occur immunologically may allow long survival of xenografts. In this review, immunolo-gic hurdles to xenotransplantation and studies for overcoming the consequences of these will be discus¬sed.
Bookmark/Search this post with
Abstract (Original Language): 
Ksenotransplantasyon, donör organ bulma konusundaki sorunları çözümleyecek en umut verici yöntem olarak görünmektedir. Ayrıca ksenotransplantas-yonda, giderek ilerleyen genetik mühendisliğinin im¬kanlarından da yararlanılabilir. Ancak filogenetik olarak farklı bireyler arasında yapılan doku yada or¬gan nakillerine en büyük engel humoral immün sis¬temden gelmektedir, özellikle doğal antikorlar ve kompleman sistemi aracılığı ile graft endoteli üzerinde oluşan immünopatolojik etkiler ksenotransplant rejeksiyonuna neden olur. Bununla birlikte; immüno¬lojik olarak oluşacak "akomodasyon" olgusu, ksenog-raftların yaşam sürelerini uzatabilir. Bu yazıda, ksenotransplantasyon için immünolojik engeller ve bun¬ların etkilerini ortadan kaldırmaya yönelik çalışma¬lar tartışılacaktır.
FULL TEXT (PDF): 
PDF icon pdf_tndt_70.pdf
  • 1
6-12
  • Turkish

REFERENCES

References: 

1. Reemtsma K. Xenografts. Transpl Proc 1989; 21 (1): 517-519.
2. Najarian JS. Overview of in vivo xenotransplantation studies: Prospects for the future. Transpl Proc 1992; 24(2): 733-738.
3. Edwards J. Complement activation by xenogeneic red blood cells. Transplantation 1981; 31: 226-27.
4. Alcxandre GPJ, Squifflet JP, De Bruyere M. et al. Pre¬sent experiences in a series of 26 ABO-incompalible li¬ving donor renal allografts. Transplant Proc 1987; 19: 4538-4542.
5. Bannett AD, Me Alack RF, Raja R et al. Experiences with known ABO-mismatched renal transplants. Trans¬plant Proc 1987; 19: 4543-4546.
6. Palmer A, Welsh K, Gjorstrup P, et al. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1989; 1: 10-12.
7. Platt JL, Vercellotti GM, Dalmasso AP, et al. Transplan¬tation of discordant xenografts: A review of progress. Immunol Today 1990; 11: 450-456. ,
8. Platt JL, Dalmasso AP, Vercellotti GM, Lindman BJ,
Turman MA, Bach FH. Endothelial cell proteoglycans in xenotransplantation. Transplant Proc 1990; 22 (3): 1066.
9. Platt JL, Bach FH. The barrier to xenotransplantation.
Transplantation 1991; 52: 937-947.
10. Hammer C. Xenotransplantation: State of art. Transplant
Proc 1993; 25 (4), suppl 3 : 35-37.
11. Bach FH. Discordant Xenografting: A summary and look
to the future. Transplant Proc 1992; 24(2): 739-742.
12. Invcrardi LA, Bender JR, Samaja M, Pardi R. The role of NK cells in the recognition of xenografts. Transplant
Proc 1992; 24:459-461.
13. Platt JL. Xenotransplantation: Immunological hurdles and prospects for future success. J Nephrol 1993; 6(4): 182-192.
14. Casali P, Notkins AL. CD5+B lymphocytes, polyreactive antibodies and the human B-cell repertoire. Immunol To¬day 1989; 10: 364-368.
15. Bcndtzen K, Sevenson M, Jonsson V, Hippe E. Autoanti-bodies to cytokines-friends or foes. Immunol Today 1990; 11: 167-169.
16. Avrameas S. Natural antibodies 1991; 12: 154-159.
17. Hammer C. Preformed natural antibodies (PNAB) and possibilities of modulation of hyperacute xenogeneic re¬jection. Transplant Proc 1989; 21: 522-523.
18. He X Tepper I, Copet L, Smith C, Rccmtsma K, Rose E. Incidence of preformed antibodies against potential xe-nodonors in human sera. Transplantation 1990; 49: 1022¬1024.
19. Platt JL, Fischel RJ, Matas AJ, Reif SA, Bolman RM, Bach FH. Immunopathology of hyperacute xenograft re¬jection in a swine-to-primate model. Transplantation
1991;52:214-220.
20. Platt JL, Lindman BJ, Chen H, Spitalnik SL, Bach FH.
Endothelial cell antigens recognized by xenoreactive hu¬man natural antibodies. Transplantation 1990; 50: 817¬822.
21. Geller RL, Bach FH, Vercellotti GM, Fischel RJ, Bol-man RM, Platt JL. Activation of endothelial cells in hyperacul xenograft rejection. Transplant Proc 1992; 24:
592.
22. Stevens RB, Platt JL. The pathogenesis of hyperacute xe-
nograft rejection. Am J Kidney Dis 1992; 220 (4) 414¬421.
23. Abbas AK, Lichtman AH, Pober JS. Cellular and Mole¬cular Immunology, WB Saunders, Philadelphia, 1991, pp 269-275.
24. Inverardi L, Samaja M, Molterlini R, et al. Early recogni¬tion for a discordant xenogeneik organ by human circula¬ting lymphocytes. J Immunol 1992; 149: 1416-1423.
25. Platt JL, VercoHotti GM, Dalmasso AP et al. Transplan¬tation of discordant xenografts: a review of progress. Im¬munol Today 1990; 11: 450-456.
11
26. Auchincloss H Jr. Xenogeneic transplantation. Transplantation 1988; 46: 1-20.
27. Turman CA, Casali P, Notkins AL, Bach FH, Platt JL. Polyreactivity and antigen specificty of human xenorcac-tive monoclonal and serum natural antibodies. Trans¬plantation 1991; 52: 710-717.
28. Figueroa J, Fuad S, Kunjummen BD, Platt JL, Bach FH. Suppresion of synthesis of natural antibodies by RS-61443: potential use in discordant xenografting. Transplantation 1993; 55: 1371-1374.
29. Geller RL, Bach FH, Turman MA, Casali P, Platt JL.
Evidence that polyreactive antibodies are deposited in re¬jected discordant xenografts. Transplantation 1993; 55: 168-172.
30. Gewurz H, Clark DS, Cooper MD, Varco RL, Good RA. Effect of cobra venom-induced inhibition of complement activity on allograft and xenograft rejection reactions.
Transplantation 1967; 5: 1296-1303.
31. Leventhal JR, Dalmasso AP, Cromwell JW, et al. Prolon¬gation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 56: 1-8.
32. Pruitt SK, Baldwin WM, Marsh HC, et al. The effect of
soluble complement receptor type I on hyperacute xe-nograft rejection. Transplantation 1991; 52: 868-873.
33. Dalmasso AP, Vercollotti GM, Platt JL, Bach FH. Inhibi¬tion of complement-mediated endothelial cell cytotoxi-city by decay accelerating factor: potential for prevention of xenograft hyperacute rejection. Transplantation 1991;
52: 530-533.
34. Akami T, Sawada R, Minato N, et al. Cytoprotective ef¬fect of CD59 antigen on xenotransplantation immunity.
Transplant Proc 1992; 24: 485-487.
35. Cary N, Moody J, Yannoutsos N, Wallwork J, White D.
Tissue expression of human decay accelerating factor, a regulator of complement activation expressed in mice: a potential approach to inhibition of hyperacute xenograft rejection. Transplant Proc 1993; 25: 400-401.

Thank you for copying data from http://www.arastirmax.com